105 related articles for article (PubMed ID: 25945730)
1. Differential Targeting of Human Topoisomerase II Isoforms with Small Molecules.
Mariani A; Bartoli A; Atwal M; Lee KC; Austin CA; Rodriguez R
J Med Chem; 2015 Jun; 58(11):4851-6. PubMed ID: 25945730
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.
Wu CC; Li TK; Farh L; Lin LY; Lin TS; Yu YJ; Yen TJ; Chiang CW; Chan NL
Science; 2011 Jul; 333(6041):459-62. PubMed ID: 21778401
[TBL] [Abstract][Full Text] [Related]
3. 4,6-Substituted-1,3,5-triazin-2(1H)-ones as monocyclic catalytic inhibitors of human DNA topoisomerase IIα targeting the ATP binding site.
Pogorelčnik B; Janežič M; Sosič I; Gobec S; Solmajer T; Perdih A
Bioorg Med Chem; 2015 Aug; 23(15):4218-4229. PubMed ID: 26183545
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
Chen W; Qiu J; Shen YM
Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
[TBL] [Abstract][Full Text] [Related]
5. Novel Deazaflavin Analogues Potently Inhibited Tyrosyl DNA Phosphodiesterase 2 (TDP2) and Strongly Sensitized Cancer Cells toward Treatment with Topoisomerase II (TOP2) Poison Etoposide.
Kankanala J; Ribeiro CJA; Kiselev E; Ravji A; Williams J; Xie J; Aihara H; Pommier Y; Wang Z
J Med Chem; 2019 May; 62(9):4669-4682. PubMed ID: 30998359
[TBL] [Abstract][Full Text] [Related]
6. Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy.
Atwal M; Lishman EL; Austin CA; Cowell IG
Mol Pharmacol; 2017 Jan; 91(1):49-57. PubMed ID: 27974636
[TBL] [Abstract][Full Text] [Related]
7. N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase.
Baviskar AT; Madaan C; Preet R; Mohapatra P; Jain V; Agarwal A; Guchhait SK; Kundu CN; Banerjee UC; Bharatam PV
J Med Chem; 2011 Jul; 54(14):5013-30. PubMed ID: 21644529
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design, synthesis and biological testing of etoposide analog epipodophyllotoxin-N-mustard hybrid compounds designed to covalently bind to topoisomerase II and DNA.
Yadav AA; Wu X; Patel D; Yalowich JC; Hasinoff BB
Bioorg Med Chem; 2014 Nov; 22(21):5935-49. PubMed ID: 25282653
[TBL] [Abstract][Full Text] [Related]
9. On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs.
Wu CC; Li YC; Wang YR; Li TK; Chan NL
Nucleic Acids Res; 2013 Dec; 41(22):10630-40. PubMed ID: 24038465
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor.
Jun KY; Lee EY; Jung MJ; Lee OH; Lee ES; Park Choo HY; Na Y; Kwon Y
Eur J Med Chem; 2011 Jun; 46(6):1964-71. PubMed ID: 21419530
[TBL] [Abstract][Full Text] [Related]
11. Producing irreversible topoisomerase II-mediated DNA breaks by site-specific Pt(II)-methionine coordination chemistry.
Wang YR; Chen SF; Wu CC; Liao YW; Lin TS; Liu KT; Chen YS; Li TK; Chien TC; Chan NL
Nucleic Acids Res; 2017 Oct; 45(18):10861-10871. PubMed ID: 28977631
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, crystal structure and antiproliferative activity of Cu(II) nalidixic acid-DACH conjugate: comparative in vitro DNA/RNA binding profile, cleavage activity and molecular docking studies.
Arjmand F; Yousuf I; Hadda Tb; Toupet L
Eur J Med Chem; 2014 Jun; 81():76-88. PubMed ID: 24826817
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of 2-phenylnaphthalenoids as inhibitors of DNA topoisomeraseIIα and antitumor agents.
Chen W; Shen Y; Li Z; Zhang M; Lu C; Shen Y
Eur J Med Chem; 2014 Oct; 86():782-96. PubMed ID: 25240702
[TBL] [Abstract][Full Text] [Related]
14. Deazaflavin Inhibitors of TDP2 with Cellular Activity Can Affect Etoposide Influx and/or Efflux.
Komulainen E; Pennicott L; Le Grand D; Caldecott KW
ACS Chem Biol; 2019 Jun; 14(6):1110-1114. PubMed ID: 31091068
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of friedelan triterpenoid analogs with DNA topoisomerase IIα inhibitory activity and their molecular docking studies.
Mandal A; Ghosh S; Bothra AK; Nanda AK; Ghosh P
Eur J Med Chem; 2012 Aug; 54():137-43. PubMed ID: 22633831
[TBL] [Abstract][Full Text] [Related]
16. Salicylate, a catalytic inhibitor of topoisomerase II, inhibits DNA cleavage and is selective for the α isoform.
Bau JT; Kang Z; Austin CA; Kurz EU
Mol Pharmacol; 2014 Feb; 85(2):198-207. PubMed ID: 24220011
[TBL] [Abstract][Full Text] [Related]
17. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological activities of topopyrones.
Zaleski PA; Maini R; Leiris SJ; Elban MA; Hecht SM
J Nat Prod; 2012 Apr; 75(4):577-85. PubMed ID: 22462811
[TBL] [Abstract][Full Text] [Related]
19. Novel ametantrone-amsacrine related hybrids as topoisomerase IIβ poisons and cytotoxic agents.
Zagotto G; Gianoncelli A; Sissi C; Marzano C; Gandin V; Pasquale R; Capranico G; Ribaudo G; Palumbo M
Arch Pharm (Weinheim); 2014 Oct; 347(10):728-37. PubMed ID: 25042690
[TBL] [Abstract][Full Text] [Related]
20. Cyclometalated platinum(II) complexes as topoisomerase IIα poisons.
Liu J; Leung CH; Chow AL; Sun RW; Yan SC; Che CM
Chem Commun (Camb); 2011 Jan; 47(2):719-21. PubMed ID: 21072335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
